Concurrent Investment Advisors LLC lessened its stake in Danaher Co. (NYSE:DHR – Free Report) by 9.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,427 shares of the conglomerate’s stock after selling 360 shares during the period. Concurrent Investment Advisors LLC’s holdings in Danaher were worth $787,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also made changes to their positions in the company. FMR LLC increased its holdings in shares of Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after acquiring an additional 3,217,631 shares during the last quarter. Van ECK Associates Corp increased its stake in Danaher by 6,862.7% during the fourth quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate’s stock valued at $213,452,000 after purchasing an additional 916,513 shares during the last quarter. Massachusetts Financial Services Co. MA increased its stake in Danaher by 17.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after purchasing an additional 535,254 shares during the last quarter. Montrusco Bolton Investments Inc. grew its position in shares of Danaher by 30.4% during the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after buying an additional 397,671 shares during the last quarter. Finally, Union Bancaire Privee UBP SA bought a new stake in shares of Danaher during the 4th quarter valued at about $74,551,000. Institutional investors own 79.05% of the company’s stock.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on the company. Barclays cut their price target on Danaher from $275.00 to $240.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. Guggenheim initiated coverage on shares of Danaher in a report on Thursday, December 19th. They set a “buy” rating and a $275.00 price target for the company. Raymond James reaffirmed a “market perform” rating on shares of Danaher in a report on Monday, February 3rd. Wells Fargo & Company reduced their target price on shares of Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. Finally, The Goldman Sachs Group set a $250.00 price target on shares of Danaher in a research note on Wednesday, January 15th. Seven analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $278.00.
Danaher Stock Up 0.9 %
Shares of Danaher stock opened at $209.86 on Monday. Danaher Co. has a 1 year low of $196.80 and a 1 year high of $281.70. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The company has a market capitalization of $151.58 billion, a P/E ratio of 39.75, a price-to-earnings-growth ratio of 2.66 and a beta of 0.83. The business has a 50-day moving average of $226.71 and a two-hundred day moving average of $246.84.
Danaher (NYSE:DHR – Get Free Report) last announced its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the prior year, the company posted $2.09 EPS. As a group, equities analysts predict that Danaher Co. will post 7.63 EPS for the current year.
Danaher Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a $0.32 dividend. This is a boost from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 annualized dividend and a yield of 0.61%. Danaher’s payout ratio is currently 20.45%.
Insider Activity at Danaher
In other news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 11.10% of the stock is currently owned by insiders.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Why Genuine Parts Company Is a Royally Good Buy Right Now
- How to Invest in Small Cap StocksĀ
- Industrials Are Quietly Outpacing the Market: 3 Stocks to Watch
- What is the MACD Indicator and How to Use it in Your Trading
- These 5 Energy Stocks Hedge Inflation With Growth Potential
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.